Sino Biological Launches 4RISE Services for AI-Designed Protein Binders

Sino Biological has launched 4RISE™, a high-throughput wet-lab validation service for AI-designed protein binders. The company says the workflow combines 3-hour cell-free protein expression with AI-ready binding data in as little as 3 days and real-time API access.
- 4RISE™ validates AI-designed protein binders using high-throughput wet-lab workflows.
- XPressMAX™ provides cell-free protein synthesis in 3 hours.
- The service delivers AI-ready binding data in as little as 3 days.
- Researchers can access structured binding data in real time through an API.
- The offering includes developability, bioactivity, and cell-based functional assays.
A faster path from protein sequence to binding data
AI-designed protein binders require laboratory testing to confirm whether they bind to their intended targets. Sino Biological says its 4RISE™ service is designed to provide that validation more quickly for researchers working in AI-driven drug discovery.
The service uses the company’s XPressMAX™ Cell-Free Protein Synthesis platform, which supports recombinant protein synthesis in 3 hours. According to Sino Biological, expression success rates exceed 99% in established workflows. The platform supports miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, allowing researchers to test different types of AI-designed candidates.
Combined with high-throughput binding analysis, the workflow can produce sequence-to-AI-ready binding data in as little as 3 days. Structured target-binding data can also be retrieved in real time through an API, supporting downstream research and analysis.
Four screening and characterization workflows
4RISE™ includes four service options aimed at different stages of binder discovery. Rapid Hit Discovery screens crude supernatants to identify binding-positive miniproteins and VHHs. Comparative Binder Screening evaluates purified candidates under standardized conditions to support prioritization.
Affinity & Kinetic Characterization provides quantitative information for lead selection. Specialized Binder Expression & Validation is designed for diverse binder formats, using tailored mammalian expression and binding analysis.
For the measurements themselves, Sino Biological says 4RISE™ uses Carterra high-throughput SPR, Biacore SPR, and Octet BLI. The company says these methods support high-throughput binding screening, kinetic analysis, and affinity determination.
The offering extends beyond binding tests. It includes more than 20 developability assays, more than 1,000 protein bioactivity assays, and more than 10 cell-based functional assays for further candidate evaluation and design optimization.
Why the service matters for AI drug discovery
AI-based protein design can generate candidate molecules, but laboratory evidence is needed to assess whether those candidates perform as intended. Sino Biological says it works with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering.
The company also says 4RISE™ validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals.
“AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, in the company’s announcement. “Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications.”
For AI-focused life sciences researchers, the service is intended to connect computational candidate generation with standardized experimental validation. Its short expression and data timelines, along with API access, could support faster feedback and repeated design iterations, according to Sino Biological.


